Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC

Figure 1

Expression pattern of KPNA2 in PDAC. (a–d) Expression analysis of KPNA2 in tumors and corresponding adjacent nontumor tissues using four independent GEO datasets (GSE15471, GSE16515, GSE62452, and GSE28735) (Student’s -test, ). (e) IHC staining of KPNA2 expression in PDAC tumor (scale bar: 100 μm). (f) IHC staining of KPNA2 expression in the engineered mouse model of KPC (scale bar: 100 μm). (g) Kaplan-Meier overall survival (OS) curves in the TCGA dataset of PDAC patients according to the mRNA expression of KPNA2, the lower quartile value of expression was utilized as a cut-off (log-rank test, ). (h) Kaplan-Meier OS curve for the MPC1 expression in the GSE71729 dataset (log-rank test, ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)